Interrogation of the frequency of nMRTF within clinical BCC samples revealed that up to 60% of naive BCCs display varying levels of nMRTF and are intrinsically resistant to SMO inhibitors ex vivo, despite no prior exposure to treatment12. This evidence concerns the gene SMO and skin basal cell carcinoma.